Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extrapulmonary small-cell carcinoma: a single-institution experience.

Jung Han Kim1, Se-Hoon Lee, Jinny Park

  • 1Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Japanese Journal of Clinical Oncology
|July 3, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review.

Blood research·2026
Same author

H<sub>2</sub>O<sub>2</sub>-scavenging intermetallic Pt<sub>5</sub>Ce/C as a highly active and durable oxygen reduction electrocatalyst.

RSC advances·2026
Same author

Allogeneic stem cell transplantation for myelofibrosis in the modern era: Single-center outcomes with DIPSS risk stratification.

Blood research·2026
Same author

A <sup>64</sup>Cu-Labeled Oxopurine Derivative for Translocator Protein-Targeted Inflammation Imaging.

Journal of labelled compounds & radiopharmaceuticals·2026
Same author

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Annals of hematology·2026
Same author

Impact of Transfusion Dependence on Clinical and Economic Burden in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Study.

Journal of blood medicine·2026

Extrapulmonary small-cell carcinoma (EPSCC) presents diverse primary sites, most commonly the uterine cervix. Except for cervical cases, EPSCC generally has a poor prognosis despite varied treatments.

Area of Science:

  • Oncology
  • Pathology

Background:

  • Extrapulmonary small-cell carcinoma (EPSCC) is a distinct clinicopathological entity.
  • This study reviews clinical features, therapy, and outcomes of EPSCC patients.

Purpose of the Study:

  • To analyze the clinical characteristics, treatment approaches, and natural progression of Extrapulmonary small-cell carcinoma (EPSCC).

Main Methods:

  • Retrospective review of medical records for patients with small-cell carcinoma (SCC) from September 1995 to December 2002.
  • Inclusion criteria: pathologically confirmed SCC outside the lung, normal chest imaging, and negative respiratory investigations.

Main Results:

  • Twenty-four EPSCC cases identified; common primary sites include uterine cervix (29%), urinary bladder (5), and colon/rectum (3).

Related Experiment Videos

  • Sixteen patients had limited disease (LD), eight had extensive disease (ED). ED patients receiving platinum-based chemotherapy had a 57% response rate but a median overall survival (OS) of 9.2 months.
  • LD SCC of the cervix showed a favorable course (5 disease-free patients, 28.4 months median follow-up), while LD SCC of other sites had a median OS of 9.6 months.

    • Conclusions:

    • Extrapulmonary small-cell carcinoma (EPSCC) originates from various sites, with the uterine cervix being the most frequent.
    • EPSCC outside the cervix typically presents a fatal prognosis with limited response to current treatments, regardless of stage.